|

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

RECRUITINGPhase 3Sponsored by Novo Nordisk A/S
Actively Recruiting
PhasePhase 3
SponsorNovo Nordisk A/S
Started2026-09-22
Est. completion2028-10-10
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations45 sites

Summary

The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Male or female (sex at birth).
* Age 18 years or above at the time of signing the informed consent.

Exclusion Criteria:

* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.
* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.

Conditions3

ObesityOverweightWeight Loss

Interventions4

Locations45 sites

First Valley Medical Group
Lancaster, California, 93534
Desert Oasis Healthcare
Palm Springs, California, 92262
Western University of Health Sciences
Pomona, California, 91766
Artemis Insitute for Clin Res
Med Home Development Grp
Washington D.C., District of Columbia, 20037

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.